Description
Histology and Cytology IVD Market Update, 2024 provides an in-depth competitive analysis of the histology/cytology market from 2023 to 2028. The forecasted market analysis from 2023 to 2028 is based on demographic trends, new technological developments, innovative products, and global market expansion. This comprehensive review offers insights into the future direction of the histology and cytology IVD market, highlighting the potential for growth and advancements.
Histology and cytology have long been essential components of pathological laboratories, offering critical insights into cells, tissues, and organs. Through histopathological examinations, a variety of diseases, including cancer, can be accurately diagnosed. Physicians rely heavily on pathological information to determine treatment plans and prognoses.
Technological Advancements
Recent technological advancements have significantly enhanced the understanding of tissue and organ structure-function relationships and their link to diseases. Innovations such as digital imaging, quantitative microscopy, precision microscopy, artificial intelligence, and virtual histology are set to revolutionize the histology/cytology industry, improving accuracy and automating workflows.
Market Segmentation
This report exclusively focuses on traditional histology and segments the market into five key areas:
- Traditional Non-PAP Stains
- PAP
- In Situ Hybridization
- Immunohistochemistry
- HPV
Key Market Participants
The report also profiles five leading companies in the market:
- Agilent
- Danaher Corporation
- Hologic
- Illumina
- Roche Diagnostics
Market Data
All market data pertains to the global market at the manufacturers’ level, focusing on manufacturer tests. The base year for data is 2023, with projections for 2028. The report provides compound annual growth rates (CAGRs) for 2023-2028. Additionally, competitive analysis and regional breakdowns for the United States, Europe, Asia-Pacific, and the Rest of the World are included.
Table of Contents
Chapter 1: Executive Summary
Industry at a Glance
Scope and Methodology
Size and Growth of the Market
- Figure 1-1: Global Histology IVD Market, 2023-2028 ($ millions)
Competitive Outlook
Chapter 2: Market Overview
Overview Of Histology/Cytology
Histology and Cancer
Advanced Analysis Solutions
- Table 2-1: Selected Advanced Histology Techniques
Laboratory Developed Tests
AI and Histology
Chapter 3: Market Size and Growth
Market Segments
- Table 3-1: Global Histology/Cytology Sales, by Type (Pap Tests, In situ hybridization, Immunohistochemistry, Traditional non-Pap stains, HPV), 2023-2028 ($ millions)
- Figure 3-1: Global Histology/Cytology IVD Market, 2023-2028 ($ millions)
- Figure 3-2: Histology/Cytology Diagnostic Market Distribution, by Broad Test Category (Pap Tests, In situ hybridization, Immunohistochemistry, Traditional non-Pap stains, HPV), 2023 (%)
Traditional Tissue Stains
- Table 3-2: Selected Vendors of Traditional Histology Stains
PAP Tests
- Table 3-3: Primary and Secondary Prevention of Cervical Cancer, Screening Responses by Country, 2022 (last updated 2022-5-6)
Immunohistochemistry and In Situ Hybridization
- Table 3-4: Selected in Situ Hybridization-based Tests
- Table 3-5: Selected IHC Test Innovations
HPV
- Figure 3-3: HPV Screening Market: HPV DNA and Pap Test Distribution of Sales, 2023
- Table 3-6: Global HPV Molecular (DNA/RNA) Test Sales Distribution, by Region (North America, Europe, Asia Pacific, RoW), 2023 (%)
- Table 3-7: Selected HPV Test Innovations
Market by Region
- Table 3-8: Global Histology/Cytology Market, by Region (North America, Europe, Asia, RoW), 2023-2028 ($ millions)
- Figure 3-4: Global Histology/Cytology Market, by Region (North America, Europe, Asia, RoW), 2023-2028 (%)
- Table 3-9: Global Histology/Cytology Sales Distribution, by Region (North America, Europe, Asia Pacific, RoW), 2023 (%)
North America
- Table 3-10: North America Histology/Cytology Market, by Segment (Pap Test, In situ hybridization, Immunohistochemistry, Traditional non-Pap test, HPV-DNA), 2023-2028 ($ millions)
- Figure 3-5: North America Histology/Cytology Market, by Segment (Pap Test, In situ hybridization, Immunohistochemistry, Traditional non-Pap test, HPV-DNA), 2023-2028 (%)
Europe
- Table 3-11: Europe Histology/Cytology Market, by Segment (Pap Test, In situ hybridization, Immunohistochemistry, Traditional non-Pap test, HPV-DNA), 2023-2028 ($ millions)
- Figure 3-6: Europe Histology/Cytology Market, by Segment (Pap Test, In situ hybridization, Immunohistochemistry, Traditional non-Pap test, HPV-DNA), 2023-2028 (%)
Asia Pacific
- Table 3-12: Asia Pacific Histology/Cytology Market, by Segment (Pap Test, In situ hybridization, Immunohistochemistry, Traditional non-Pap test, HPV-DNA), 2023-2028 ($ millions)
- Figure 3-7: Asia Pacific Histology/Cytology Market, by Segment (Pap Test, In situ hybridization, Immunohistochemistry, Traditional non-Pap test, HPV-DNA), 2023-2028 (%)
Rest of World (RoW)
- Table 3-13: Rest of World (RoW) Histology/Cytology Market, by Segment (Pap Test, In situ hybridization, Immunohistochemistry, Traditional non-Pap test, HPV-DNA), 2023-2028 ($ millions)
- Figure 3-8: Rest of World (RoW) Histology/Cytology Market, by Segment (Pap Test, In situ hybridization, Immunohistochemistry, Traditional non-Pap test, HPV-DNA), 2023-2028 (%)
Competitive Analysis
- Table 3-14: Revenues of the Major Histology Companies, 2017-2023 ($ millions, estimated)
- Table 3-15: Pathology Launches by Roche
The Commercial Outlook for Histology
Chapter 4: Major Market Participants
Abbott Diagnostics
- Table 4-1: Abbott Corporate Summary
- Table 4-2: Abbott Revenue History, 2017-2023 ($ million)
Agilent
- Table 4-3: Agilent Corporate Summary
- Table 4-4: Agilent Diagnostic Revenues, 2017-2023 ($ millions)
- Figure 4-1: Agilent Revenues, by Group, 2022-2023 ($ millions)
Becton, Dickinson and Company
- Table 4-5: Becton Dickinson Corporate Summary
- Table 4-6: BD Revenue History, 2017-2023 ($ million, FYE Sept 30)
Biocare Medical
- Table 4-7: Biocare Medical Corporate Summary
BioGenex
- Table 4-8: BioGenex Corporate Summary
Danaher Corporation
- Table 4-9: Danaher Corporation Summary
- Table 4-10: Danaher Revenue History, 2017-2023 ($ million, estimated)
- Figure 4-2: Danaher Diagnostics (Recurring/Nonrecurring), Full Year 2022 and 2023 ($ millions)
Hologic
- Table 4-11: Hologic Corporate Summary
- Table 4-12: Hologic Revenue History, 2017-2023 ($ million, estimated)
- Figure 4-3: Hologic Diagnostic Product Revenues, FY 2022 and FY 2023 ($ million)
Illumina, Inc
- Table 4-13: Illumina Corporate Summary
- Table 4-14: Illumina Diagnostics Revenues, 2017-2023 ($ millions)
- Figure 4-4: Illumina Diagnostic Revenues, 2022-2023 ($ millions)
Medimeas
- Table 4-15: Medimeas Corporate Summary
QIAGEN N.V.
- Table 4-16: QIAGEN Corporate Summary
- Table 4-17: QIAGEN Revenue History, 2017-2023 ($ million, estimated)
Roche Diagnostic (Roche Tissue Diagnostics)
- Table 4-18: Roche Diagnostic Corporate Summary
- Table 4-19: Roche Revenue History ($ million, estimated)
- Figure 4-5: Roche Diagnostic Performance, Full Year 2022 and 2023 (CHF Mn)
Sysmex
- Table 4-20: Sysmex Corporate Summary
- Table 4-21: Sysmex Revenue History, 2017-2023 ($ million, estimated)
Thermo Fisher Scientific
- Table 4-22: Thermo Fisher Corporate Summary
- Table 4-23: Thermo Fisher Revenue History, 2017-2023 ($ million, estimated)